

# Georgina L Ryland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4784548/publications.pdf>

Version: 2024-02-01

48  
papers

2,056  
citations

430874

18  
h-index

254184

43  
g-index

52  
all docs

52  
docs citations

52  
times ranked

5227  
citing authors

#	ARTICLE	IF	CITATIONS
1	CONTRA: copy number analysis for targeted resequencing. <i>Bioinformatics</i> , 2012, 28, 1307-1313.	4.1	308
2	Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles. <i>PLoS Genetics</i> , 2012, 8, e1002894.	3.5	186
3	An activating <i>Pik3ca</i> mutation coupled with <i>Pten</i> loss is sufficient to initiate ovarian tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 553-557.	8.2	174
4	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. <i>Oncotarget</i> , 2015, 6, 37663-37677.	1.8	142
5	Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. <i>Genome Medicine</i> , 2015, 7, 87.	8.2	126
6	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3935.	12.8	110
7	<i>RNF43</i> is a tumour suppressor gene mutated in mucinous tumours of the ovary. <i>Journal of Pathology</i> , 2013, 229, 469-476.	4.5	102
8	Inferring copy number and genotype in tumour exome data. <i>BMC Genomics</i> , 2014, 15, 732.	2.8	102
9	Loss of heterozygosity: what is it good for?. <i>BMC Medical Genomics</i> , 2015, 8, 45.	1.5	85
10	Analysis of <i>RAD51C</i> germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. <i>Human Mutation</i> , 2012, 33, 95-99.	2.5	64
11	Frequent activating <i>STAT3</i> mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. <i>Oncotarget</i> , 2018, 9, 36126-36136.	1.8	62
12	Multiplexed transcriptome analysis to detect <i>ALK</i> , <i>ROS1</i> and <i>RET</i> rearrangements in lung cancer. <i>Scientific Reports</i> , 2017, 7, 42259.	3.3	49
13	Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 552-560.	1.4	49
14	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.		45
15	A simple consensus approach improves somatic mutation prediction accuracy. <i>Genome Medicine</i> , 2013, 5, 90.	8.2	33
16	Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing. <i>Journal of Clinical Pathology</i> , 2018, 71, 895-899.	2.0	28
17	MicroRNA Genes and Their Target 3' Untranslated Regions Are Infrequently Somatic Mutated in Ovarian Cancers. <i>PLoS ONE</i> , 2012, 7, e35805.	2.5	27
18	ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4093-4097.	5.2	25

#	ARTICLE	IF	CITATIONS
19	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	5.5	21
20	JAFAL: detecting fusion genes with long-read transcriptome sequencing. <i>Genome Biology</i> , 2022, 23, 10.	8.8	20
21	Enhancer retargeting of <i>CDX2</i> and <i>UBTF::ATXN7L3</i> define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. <i>Blood</i> , 2022, 139, 3519-3531.	1.4	20
22	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1758.	4.1	19
23	ASXL1 c.1934dup;p.Gly646Trpfs*12" a true somatic alteration requiring a new approach. <i>Blood Cancer Journal</i> , 2017, 7, 656.	6.2	18
24	Incidental detection of germline variants of potential clinical significance by massively parallel sequencing in haematological malignancies. <i>Journal of Clinical Pathology</i> , 2018, 71, 84-87.	2.0	18
25	Analysis of the Mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer. <i>BMC Cancer</i> , 2011, 11, 173.	2.6	17
26	Bioinformatics Pipelines for Targeted Resequencing and Whole-Exome Sequencing of Human and Mouse Genomes: A Virtual Appliance Approach for Instant Deployment. <i>PLoS ONE</i> , 2014, 9, e95217.	2.5	17
27	CNSpector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing. <i>Scientific Reports</i> , 2019, 9, 6426.	3.3	17
28	Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes. <i>Haematologica</i> , 2020, 106, 64-73.	3.5	14
29	A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability. <i>British Journal of Haematology</i> , 2020, 190, e297-e301.	2.5	14
30	Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 606-612.	2.5	8
31	Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour <i>scDNA</i> using a single hybridisation-based next generation sequencing assay. <i>British Journal of Haematology</i> , 2018, 183, 146-149.	2.5	8
32	Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome. <i>Blood</i> , 2018, 131, 699-702.	1.4	5
33	Inotuzumab ozogamicin resistance associated with a novel <i>CD22</i> truncating mutation in a case of acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 123-126.	2.5	5
34	T Cell Landscape of Immune Aplastic Anemia Reveals a Convergent Antigen-Specific Signature. <i>Blood</i> , 2019, 134, 108-108.	1.4	5
35	Canary: an atomic pipeline for clinical amplicon assays. <i>BMC Bioinformatics</i> , 2017, 18, 555.	2.6	4
36	Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas. <i>American Journal of Pathology</i> , 2014, 184, 1871-1876.	3.8	2

#	ARTICLE	IF	CITATIONS
37	Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. <i>Leukemia and Lymphoma</i> , 2018, 59, 992-995.	1.3	2
38	Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants. <i>Leukemia and Lymphoma</i> , 2020, 61, 1257-1259.	1.3	2
39	T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection. <i>Bone Marrow Transplantation</i> , 2021, 56, 2582-2590.	2.4	2
40	Methylâ€CpG binding domain 4, DNA glycosylase ( <sc>MBD4</sc> )â€associated neoplasia syndrome associated with a homozygous missense variant in <i>MBD4</i> : Expansion of an emerging phenotype. <i>British Journal of Haematology</i> , 2022, , .	2.5	2
41	Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH. <i>Leukemia and Lymphoma</i> , 2021, 62, 3060-3062.	1.3	1
42	Clinical Determinants of T-Cell Receptor Diversity after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1997-1997.	1.4	1
43	Direct evidence of a clonal and tumor-directed T cell response to prostate cancer brachytherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 22-22.	1.6	1
44	Abstract B08: Genomics analyses of less common epithelial ovarian cancer subtypes.. , 2016, , .		0
45	Providing Diagnoses in Bone Marrow Failure Syndromes through Multimodal Comprehensive Genomic Evaluation and Multidisciplinary Care: The Melbourne Genomics Health Alliance Bone Marrow Failure Flagship. <i>Blood</i> , 2018, 132, 3867-3867.	1.4	0
46	Cnspectorx - Copy Number Assessment at a Genome Level from Targeted Sequence Data Optimized for Hematological Malignancy. <i>Blood</i> , 2019, 134, 3378-3378.	1.4	0
47	Longitudinal Genomic Characterization Using Cell-Free DNA in Patients with Idiopathic Aplastic Anemia. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
48	580â€...High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, , .		0